title: Administration of enoximone in cardiogenic shock.
abstract: Thirteen patients in severe cardiogenic shock, persisting despite the use of adrenergic agents, were treated with enoximone, a recently available phosphodiesterase inhibitor. Cardiogenic shock was characterized by low cardiac output (less than 2.5 liter.min-1.m-2), elevated pulmonary artery balloon-occluded pressure (greater than or equal to 15 mm Hg), decreased urine output (less than 20 ml.hour-1) and increased blood lactate (greater than or equal to 2.0 mEq.liter-1). Ten patients were mechanically ventilated. A short-term intravenous infusion of 0.5 mg.kg-1 in 20 minutes of enoximone resulted in significant increases in cardiac index (from 1.8 +/- 0.3 to 2.9 +/- 0.3 liter.min-1.m-2, p less than 0.001) and stroke index (from 17.8 +/- 3.3 to 21.9 +/- 5.1 ml.m-2, p less than 0.001) and significant decrease in pulmonary artery balloon-occluded pressure (from 21.7 +/- 5.8 to 19.8 +/- 6.0 mm Hg, p less than 0.01) without a consistent change in mean arterial pressure (from 79 +/- 8 to 76 +/- 9 mm Hg, difference not significant). Enoximone administration decreased arterial oxygen tension (from 108 +/- 42 to 94 +/- 36 mm Hg, p less than 0.01) and increased venous admixture (from 12.8 +/- 6.5 to 16.0 +/- 8.0%, p less than 0.01). In 8 patients, a second infusion of 0.5 mg.kg-1 immediately thereafter amplified these changes. All patients but one survived the episode of cardiogenic shock and 5 patients left the hospital alive. These results indicate that the addition of enoximone to adrenergic agents in the treatment of cardiogenic shock can markedly increase cardiac output and stroke volume without substantial effects on arterial pressure.
authors.affiliation: Department of Intensive Care, Erasme University Hospital, Brussels, Belgium.
authors.forename: J L
authors.initials: JL
authors.lastname: Vincent
authors.forename: E
authors.initials: E
authors.lastname: Carlier
authors.forename: J
authors.initials: J
authors.lastname: Berré
authors.forename: C W
authors.initials: CW
authors.lastname: Armistead
authors.forename: R J
authors.initials: RJ
authors.lastname: Kahn
authors.forename: E
authors.initials: E
authors.lastname: Coussaert
authors.forename: F
authors.initials: F
authors.lastname: Cantraine
mesh_terms: D001784:Blood Gas Analysis; D017335:Enoximone; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D012770:Shock, Cardiogenic / Q000097:blood / Q000188:drug therapy* / Q000401:mortality
chemical_list: D007093:Imidazoles; D017335:Enoximone